Natural Prenylchalconaringenins and Prenylnaringenins as Antidiabetic Agents: α-Glucosidase and α-Amylase Inhibition and in Vivo Antihyperglycemic and Antihyperlipidemic Effects.
Hua SunDong WangXiaotong SongYazhou ZhangWeina DingXiaolin PengXiaoting ZhangYashan LiYing MaRunling WangPeng YuPublished in: Journal of agricultural and food chemistry (2017)
Inhibition of α-glucosidase and α-amylase decreases postprandial blood glucose levels and delays glucose absorption, making it a treatment strategy for type 2 diabetes. This study examined in vivo and in vitro antidiabetic activities of natural prenylchalconaringenins 1 and 2 and prenylnaringenins 3 and 4, found in hops and beer. 3'-Geranylchalconaringenin (2) competitively and irreversibly inhibited α-glucosidase (IC50 = 1.08 μM) with activity 50-fold higher than that of acarbose (IC50 = 51.30 μM) and showed moderate inhibitory activity against α-amylase (IC50 = 20.46 μM). Docking analysis substantiated these findings. In addition, compound 2 suppressed the increase in postprandial blood glucose levels and serum levels of total cholesterol and triglycerides in streptozotocin-induced diabetic mice. Taken together, these results suggest that 2 has dual inhibitory activity against α-glucosidase and α-amylase and alleviates diabetic hyperglycemia and hyperlipidemia, making it a potential functional food ingredient and drug candidate for management of type 2 diabetes.
Keyphrases
- blood glucose
- glycemic control
- molecular docking
- type diabetes
- diabetic rats
- high fat diet
- molecular dynamics simulations
- blood pressure
- oxidative stress
- high glucose
- insulin resistance
- human health
- cardiovascular disease
- drug induced
- molecular dynamics
- mouse model
- risk assessment
- adipose tissue
- high intensity
- low density lipoprotein
- endothelial cells
- emergency department
- combination therapy
- replacement therapy
- adverse drug
- climate change
- smoking cessation